Twist Bioscience Co. (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $48.22.

Several research firms have issued reports on TWST. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Guggenheim began coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. Barclays lowered their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. TD Cowen raised their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $37.26 on Thursday. The firm’s 50 day simple moving average is $47.98 and its 200 day simple moving average is $42.65. Twist Bioscience has a one year low of $14.42 and a one year high of $60.90. The company has a market cap of $2.18 billion, a PE ratio of -11.09 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the previous year, the business posted ($1.01) EPS. The firm’s revenue for the quarter was up 27.7% compared to the same quarter last year. Equities research analysts expect that Twist Bioscience will post -3.13 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 842 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total transaction of $41,182.22. Following the completion of the sale, the chief financial officer now owns 73,602 shares in the company, valued at approximately $3,599,873.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the sale, the chief operating officer now owns 171,212 shares in the company, valued at approximately $9,694,023.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Laponis sold 842 shares of Twist Bioscience stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total transaction of $41,182.22. Following the transaction, the chief financial officer now directly owns 73,602 shares in the company, valued at $3,599,873.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,483 shares of company stock worth $781,448. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in Twist Bioscience by 34.8% during the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after acquiring an additional 44,349 shares during the last quarter. UBS Group AG boosted its holdings in shares of Twist Bioscience by 106.4% in the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock worth $7,868,000 after buying an additional 110,036 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in shares of Twist Bioscience by 2.9% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after buying an additional 99,511 shares during the last quarter. SageView Advisory Group LLC purchased a new position in shares of Twist Bioscience in the 1st quarter worth about $1,144,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Twist Bioscience in the 1st quarter worth about $300,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.